S. Sarkissian

Second-Generation Brutons Tyrosine Kinase Inhibitors

S. Sarkissian, 2017 .

Atypical haemolytic-uraemic syndrome due to heterozygous mutations of CFH/CFHR1-3 and complement factor H 479.

Richard J. H. Smith, I. Weitz, P. Chaudhary, 2014, Blood transfusion = Trasfusione del sangue.

Hemophagocytic lymphohistiocytosis in the setting of HELLP Syndrome

Y. Khan, E. Brem, S. Sarkissian, 2018, Clinical case reports.

PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence

J. Chao, S. Klempner, P. Tran, 2017, Gastrointestinal cancer : targets and therapy.

Blockade of ARV7:HIF1α heterodimers after topotecan reverses enzalutamide resistance in 22Rv1 cells.

Nathan Farrokhian, J. Fruehauf, Jai-Hyun Kim, 2016 .

Successful Treatment of Macrophage Activation Syndrome and Symptom of Inappropriate Anti- Diuretic Hormone in Chronic Natural Killer Cell Lymphoproliferative Disorder with Cyclophosphamide

S. Sarkissian, 2018 .

Pazopanib and taxane combinations for metastatic or recurrent soft tissue sarcoma: A retrospective case series.

J. Fruehauf, S. Sarkissian, 2016 .

Renal Manifestations of Alternate Complement Pathway Dysregulation

M. Tran, K. Kahlon, P. Siaghani, 2015 .